GCS Research Progress
Research Progress Update (October 18, 2018)
We’re happy to announce the progress that our dedicated research teams have made since our last update! This is solely possible because of the funds that you have donated to The GCS Project ($300,000 for this first phase work) and the highly detailed work from the researchers who are so committed to our goals.
The Harvard research team, under the direction of Dr. Priscilla Brastianos, and the University of Alabama (UAB) research team, under the direction of Dr. Michael Birrer, have completed whole exome and transcriptome data analysis on 133 tumor tissue samples. Our science page breaks this down (see “The Science”). In lay terms, this means that they have started to make progress in understanding the genetic underpinnings of metastatic MMMT/carcinosarcoma!
The research teams will be combining the analyses from the unique cutting-edge analytic platforms to understand the genetic mechanisms that drive metastatic carcinosarcoma. The next phase of this work is set to begin this fall. The results of this next phase are expected by the end of the summer of 2019. We will keep you posted as we learn more about this unique research into GYN carcinosarcoma.
We appreciate your continued help as we move this critical research forward!
Please DONATE HERE.
Research Progress to Date (Jan. 2018)
The main focus of the GCS Project’s research initiative has been to characterize the genetic and epigenetic landscape of a group of primary and metastatic carcinosarcoma tumor samples. Please see The Science section for an explanation of how and why we’re doing this.
To date we have been able to begin performing next-generation sequencing and DNA methylation studies on over 100 tumor samples. The majority of the sequencing is complete and there will be about 1-2 months required for analysis of the large amount of data generated.
This work has only been possible thanks to the overwhelming support the GCS Project has received through generous donations from the amazing community that has formed around this group. Looking forward, we hope to expand the sequencing efforts to include more tumor samples and utilize more advanced sequencing technologies, such as whole genome sequencing or single cell sequencing technologies. This research will also lead into the development of clinical trials which require significant funding resources. We hope to have your continued support throughout this mission and whatever comes next!
Please DONATE HERE.